Endonovo Therapeutics Inc (PK) (ENDV) 뉴스

97 Million shares added to the float in the past week. 
22% increase. 

LOL, you can't make this shit up!

Are you aware that ENDV lost a lawsuit and there will be a minimum of 4 Billion shares added to the float?  The plantiff will just unload their shares on a high volume day.
It will be extremely difficult for this to have any significant rise in SP.

Now it's time for good news.

Since you are keeping watch on the share structure, you will notice that from Jan 3 to Jan 10, the unrestricted shares increased by 86 million shares. An increase of 24% in just 1 week. 😯 

Are they going to get any positive news?

Do you work for Trillium to help promote the stock to assist with making a market for them to dump their shares?

This is certainly not the bottom. If you believe it is, consider it will remain at the bottom until Trillium sells their 4 - 7 Billion shares. 
They will dump their shares into any attempted rally. 
Do you realize the authorized shares is only 2.5 Billion? That is not enough room for Trillium to unload their shares. If ENDV does not increase the A/S, this will surely reverse split and then continue to fall as Trillium dumps shares to get their money.
Please explain how this is a good investment at the current time?

LOL! Completely clueless. Doesn't understand markets.

Do you guys work for MMs? 

LOL! Still trying to convince others to buy this scam.

This belongs in Bankruptcy Court not on the pink sheets. The balance sheet is a disaster.

If you believe it, please you don't buy it. Who cares this is already bottom.

No end in sight to this dilution...

If anyone does not believe the $2.9 million settlement as being real, you can see it posted on OTC Markets by ENDV themselves.
https://www.otcmarkets.com/stock/ENDV/disclosure

And magically he disappeared!

What do you have to say about Case No CACE24009960?  The court issued an order approving a settlement of $2,896,956.15 of the Company’s outstanding debt in 
exchange for the issuance of shares. The shares will be free of any restriction and be marketable securities.
Billions of shares will be diluted based on current SP.

LOL, trying too hard to fish for suckers!

$ENDV NO OS CHNAGE

ENDV Security Details
Share Structure
Market Cap Market Cap
435,097 01/03/2025
Authorized Shares
2,500,000,000 01/03/2025
Outstanding Shares
543,871,313 01/03/2025
Restricted
195,293,179 01/03/2025
Unrestricted
348,578,134 01/03/2025

The record date is crucial for determining eligibility, but as of now, no official record date for the SofPulse dividend has been announced in public statements.

They will fund all those things with their overdrawn bank account and zero sales for last quarter! LOL!

Give us a break.

Thanks! one last question:

How do they determine which ENDV shareholders get the stock dividend? Is it "shareholders as of a certain date," and if so, what is that date?

Summary of Endonovo’s Restructured Business Model

Focus on Digital Health and AI Integration:

Endonovo Therapeutics (ENDV) is reorganizing to develop an integrated AI-powered digital healthcare and wellness platform.
The platform aims to enhance patient engagement, streamline access for healthcare providers, and expand retail sales of wellness and medical products.

Expansion into the Wellness Market:

ENDV is entering the $4.3 trillion global wellness market (projected to reach $7 trillion by 2025) with a focus on e-commerce.
Its platform will feature AI-integrated e-commerce for wellness products, including the company’s Pulsed Electro Magnetic Field (PEMF) multi-coil technology.

Market Potential and AI Differentiation:

The digital health market, valued at $375.99 billion in 2022, is projected to grow to $1.965 trillion by 2030 at a CAGR of 23.3%.
ENDV's AI integration will provide advanced analytics, predictive marketing, and enhanced customer engagement, setting its platform apart from competitors.

Strategic Goals:

Transform patient care across medical and wellness industries.
Utilize AI for better insights into customer behavior, targeted marketing, and efficient customer support.

Company Structure:

Digital Health and Wellness Division: Focused on the AI-powered platform and e-commerce marketplace.
Legacy Division: Developer of non-invasive wearable Electroceutical® devices for general wellness.

LOL! Repeating the same BS as the last pump and dumper!

This company's contraption doesn't work like they said it did. It lacks real studies. All their scientists left to start their own competitor company as Craig previously posted. They originally were going to acquire this technology for $28 million, then sued and bought it for $4.5 million which is probably what it was worth and proceeded to destroy all its value by proving they couldn't sell the product, dropping the concussion studies, and suing their competitors and failing. So, how on God's green earth is the valuation supposed to suddenly increase over 10x what they paid for it? I guess they plan to sprinkle fairy dust on it.

It has been a year and they still have not gotten it done, guess why? Nobody will issue a valuation for them because they could get sued. Nobody is going to finance it to go onto NASDAQ. It takes around $10 million to get on. Lastly, the debt holders will be the fist to dump the shares in order to get their money, which they will convert to freely traded shares long before any retail investor can. This is another one of the CEO's scams to keep milking money out of investors.

1. Will SofPulse Be Public or Private?

Initial Status: SofPulse, Inc. will remain private at the time of acquisition completion.

Future Plans:
SofPulse intends to meet the regulatory requirements for a NASDAQ listing, suggesting that it plans to become a publicly traded company in the near future.

2. If SofPulse Is Going Public, Will They Have an IPO or Buy a Shell?

Likely Approach:
Based on the announcement, SofPulse plans to go public through a direct listing or IPO on NASDAQ. This process involves filing with the SEC and meeting NASDAQ's listing criteria.
There is no indication of using a reverse merger with a shell company, though it could remain an option if a direct listing proves challenging.

3. Would ENDV Shareholders Get Restricted SofPulse Shares? If Restricted, When/How Can They Sell?

Restricted Shares:
The shares issued to ENDV shareholders will likely be restricted, meaning they cannot be sold immediately upon receipt.

Restriction Period: Restricted shares typically have a lock-up period (commonly 6–12 months) during which they cannot be traded.

Selling Process:
After the restriction period expires, shareholders may need to comply with Rule 144 of the Securities Act to sell their shares, including filing appropriate documentation.

4. If ENDV Shareholders Get a Dividend... Where Will the New SofPulse Entity Get $40 Million?

Source of Funds:
Stock, Not Cash: The $40 million dividend will be issued in SofPulse restricted stock, not cash. SofPulse, Inc. is not required to have $40 million in cash on hand to fulfill this
commitment.

Capital Raise: SofPulse plans to raise up to $500,000 in a pre-money valuation of $10 million. Future funding rounds or operational revenue may support the valuation and company growth.

Valuation-Linked Payment:
If the updated third-party valuation exceeds $50 million, the additional amount will be paid through a senior note convertible into NASDAQ-listed marketable securities.

Can you explain how this distribution to ENDV shareholders would work?

Will SofPulse be public or private?

If SofPulse is going public, will they have an IPO or will they buy a shell?

Would ENDV shareholders get restricted SofPulse shares? If restricted, when/how can they sell?

If ENDV shareholders get a dividend... 80% of $50 million is $40 million. Where will this new SofPulse entity get $40 million?

Thanks!

$ENDV Benefits for Common Shareholders from the SofPulse Transaction
Stock Dividend or Alternative Mechanism:

As part of the agreement, 80% of the $50 million in restricted stock (priced at $5.00 per share) from SofPulse, Inc. will be issued to Endonovo’s (ENDV) shareholders. This provides a direct benefit to common shareholders, effectively transferring a portion of the value from the sale to them.
Potential Uplisting to NASDAQ:

SofPulse, Inc. has committed to fulfilling regulatory requirements for a NASDAQ listing. This uplisting could significantly increase the liquidity and perceived value of the issued shares, benefiting shareholders holding the restricted stock.
Additional Valuation-Based Payments:

A third-party valuation may determine the assets' value to be higher than $50 million (up to $100 million). The difference will be issued to ENDV in the form of a senior note, which could further increase the benefits distributed to shareholders.
Strengthened Future Prospects:

SofPulse’s plans for substantial growth, including:
Expanding Federal Supply Schedule contracts with the VA and Department of Defense.
Developing international markets.
Targeting annual revenues of $100 million by 2025.
Shareholders may benefit if the company achieves these projections and their issued shares gain value over time.
ENDV's Continued Operations:

ENDV will retain its telehealth division and mergers/acquisitions division, providing shareholders with additional growth opportunities in other sectors.
Capital Raise and Strategic Expansion:

SofPulse’s $500,000 capital raise at a pre-money valuation of $10 million may position the company for sustained growth, indirectly supporting shareholder value.

$ENDV SofPulse, a FDA Cleared medical device company specializing in non-invasive microcurrent therapy, has undergone several valuations in recent years:

2018 Valuation: A third-party assessment valued SofPulse's intellectual property and assets at $75 million.

2023 Agreement: Endonovo Therapeutics, the parent company, entered into a definitive agreement to sell SofPulse's business and medical intellectual property to SofPulse, Inc. for a minimum of $50 million. The final purchase price is subject to an updated valuation by a qualified third party, with estimates ranging between $50 million to $100 million.

Another Pump & Dump Scammer shows up! How original!

Where is the $50 million?

https://www.otcmarkets.com/stock/ENDV/news/Endonovo-Signs-Definitive-Agreement-to-Sell-SofPulse-Brand-Business-and-IP-to-SofPulse-Inc-for-a-minimum-of-50-Million?id=423534

Is ANY part of that $50 million going to be in cash? If so, when will it appear on the balance sheet?

If it's all going to be in SofPulse stock...... then this is a scam like the LLBO scam, where LLBO spun off their IP to a company called Cyrcadia. LLBO shareholders were left holding a bag of nothing.

Cyrcadia raised some money but when Cyrcadia could no longer convince anyone to invest, it all disappeared.

There is a reason for the SP being this low.
Just scroll down and read the posts.
Major dilution going to be happening due to lawsuit settlement.
Look at the dilution that happened just a few weeks ago. That is a drop in the bucket compared to what is coming.

Low OS. I have never seen this low OS in OTC at sub penny level.

Pre market volume

Piece of shit SCAM!

$ENDV Development of Endonovo Digital Wellness Market Place


The company looks to expand its operations and enter the Wellness Industry to market wellness and medical products. In 2024, the wellness market is valued as a $4.3 trillion dollar industry that is expected to expand to $7 trillion dollars by 2025, as reported by statisa.com. ENDV’s wellness platform will feature wellness and medical products and services, including its non-medical Pulsed Electro Magnetic Field (PEMF) multi-coil technology, on an AI integrated e-commerce platform/marketplace with distribution through network platforms.

New Target Price is $0.0001 Par Value

Given the last closing price of $0.0004 conversions will be taking place at a 50% discount which is $0.0002 which will drive down the stock price to that value over time. The exact timing is unknown and depends on the rate of selling on behalf of Trillium Partners. A reverse stock split is also on the horizon because they don't have enough authorized shares to cover even half of the amount that is going to be converted into freely traded stock at near par value.

This company's stock is valued at essentially ZERO due to the amount of debt that the company is holding. I don't believe they can sell all that stock to cover the debt and this is heading to a bankruptcy court. I believe Collier is on the hook for some money based on the documents filed a few years ago. My take is that he clears the debt he is a guarantor to before he throws this into bankruptcy. Their spin-out is not working because 1.) Ira cannot raise money based on a bloated valuation and 2.) Collier proved that the pain management device has no lucrative commercial viability.

They bought these assets for $4.5 million several years ago and since then have only tanked the valuation because they abandoned all the potentially lucrative applications of the technology such as the treatment of brain injury and they proved that their pain management device was not commercially viable. Simply put, acquiring this company at a $75 million valuation would produce a company who's only "asset" would be goodwill created by the bloated acquisition price.

In just 1 week, the unrestricted share count increased 27%. 😯
273.2M to 347.5M

It appears to me the selling of those shares has commenced. This stock is doomed. Even trying to flip it at this point is not worthwhile. Trillium will sell/dump into any potential rally. 

It means a R/S and/or increase in Authorized shares is coming.

This notice is also very late, a month late. Very likely we already had a conversion at $0.00025-$0.0003

If those shares are issued at a SP of .0004, that would equate to 7 Billion shares. 😯. 
The A/S is only 2.5B at the current time. 
Wonder if all this volume and current Twitter pumping is trying to increase the SP so that the shares are not issued so cheaply. 😄

BUYER BEWARE: $2.9 Million in debt to be converted at a 50% discount.

ENDV just lost a lawsuit and filed the following today:

On November 14, 2024, in a case entitled Trillium Partners, L.P. (“Trillium”) v Endonovo Therapeutics, Inc. (the “Company”) in the Circuit Court for the 17th Judicial Circuit in and for Broward County Florida (Case No CACE24009960), the court issued an order (the “Order”) approving a settlement of $2,896,956.15 of the Company’s outstanding debt in exchange for the issuance of shares at a 50% discount to market under Section 3(a)(10) of the Securities Act of 1933, as amended. The shares, when issued pursuant to the Order, will be free of any restriction and be marketable securities. As a result of the Order, the Company’s outstanding indebtedness was reduced from approximately $2,896,956.15. The sale of shares under the Order, which has not yet commenced, may have a depressive affect on the market for the Company’s shares.

He's a scammer who works as a flooring salesman at his day job & literally every single ticker he's tried to pump he's had inside ties with. He's lied to & led his dumbass followers to financial ruin (CBIH, KYNC, ENDV, ASTA, & many more). He - like the tickers he pushes - pure garbage 🚮

BUYER BEWARE: 71.7 Million shares added in last 30 days.

New OS is 468.5 million shares as of December 6, that is compared to 396.8 million shares on November 8. Since the stock closed at an all time low of $0.0006 on multiple days, these conversions might be at $0.0003 per share based on past conversions at 50% discount. This stock will end up at par value pretty soon which means the stock is worthless and the only real stakeholders are the debt holders.

They claim to be doing a REORGANIZATION

They will make those claims using those types of words for as long as possible before filing bankruptcy. Except when they file bankruptcy it will have no reorganization plan in place. They will do so because of they can convert some of their debt to equity Collier can put more money in his pocket.

Their quarterly report that was filed on Nov 13 shows their bank account overdrawn $330.
They owe $26.2 million.

It also shows Alan Collier has raised $44 million which tells me that he has lived a very expensive lifestyle while shareholders have lost money since day 1 and continue to lose money because unfortunately most investors don't know any better.

If there are people on this board posting positive things about Collier, Endonovo, the stock or even the product I would ask them to reply to this message board by picking a place in NYC that we can meet for 15 minutes. You can make it a public space. I just want the opportunity to see and speak to the person or people that are dullards in their belief of anything positive about this entire situation.

Strange how the day before the PR was released, there was high volume trading activity.
Then the day the PR is released, there was no volume or reaction to the news by the general public. 🤨

https://x.com/endonovoinc/status/1865030447333544362?s=46&t=ZV-JoM4olm35bFSad3ozrw

LOL. Using the AI buzzword to pump the stock!

These idiots haven't done anything in 2 years. They have no sales and no money to do anything so how exactly are they to build anything?

They have been putting out PR's for over two years and have done nothing they said in any of those bullshit PRs. In fact, they are in a worse condition having been delisted to the pink sheets and having their bank account overdrawn.

The reality is that this is a pump and dump PR to support the tens of millions of shares that are being converted at near par value. It is also Colliers only way to keep stealing from shareholders and not have to go out and get a job!

https://x.com/jeff_lien/status/1864662260498747654?s=46&t=ZV-JoM4olm35bFSad3ozrw

Endonovo Restructures Business as Developers of Integrated AI Digital Health and Wellness Platform

LOS ANGELES, CA, UNITED STATES, December 4, 2024 /EINPresswire.com/ -- Endonovo Restructures Business as Developers of Integrated AI Digital Health and Wellness Platform

Endonovo Therapeutics, Inc. (OTCPK: ENDV) announced today that it has implemented a reorganization of business focusing on the development of a comprehensive digital healthcare and wellness platform with integration of artificial intelligence (AI) technologies. AI integrated services and technology will streamline access for healthcare providers, enhance patient engagement and expand retail sales of wellness and medical products to capitalize on and grow within the expanding digital health and wellness markets.

Development of Endonovo Digital Wellness Market Place

The company looks to expand its operations and enter the Wellness Industry to market wellness and medical products. In 2024, the wellness market is valued as a $4.3 trillion dollar industry that is expected to expand to $7 trillion dollars by 2025, as reported by statisa.com. ENDV’s wellness platform will feature wellness and medical products and services, including its non-medical Pulsed Electro Magnetic Field (PEMF) multi-coil technology, on an AI integrated e-commerce platform/marketplace with distribution through network platforms.

Alan Collier, CEO of Endonovo Therapeutics, commented on the launch: "We are thrilled to be developing a digital healthcare and wellness platform with AI integration. Moving forward, our company mission will be to transform and improve patient care in all areas of the medical and wellness industries. Our proprietary digital health and wellness platform will help companies engage directly with retail customers, patients and healthcare providers.

Digital Health Care Market Opportunities

The digital health market size was valued at USD $375.99 billion in 2022 and is projected to grow to USD $452.79 billion in 2023 to USD 1,965.30 billion by 2030, exhibiting a CAGR of 23.3% during 2023-2030. North America dominated the global market with a share of 40.79% in 2022: reports Fortunebusinessinsites.com.

AI Integration Helps to Set ENDV Digital Platform Apart from Others

ENDV digital health and wellness systems AI integration will extend into marketing automation, where predictive analytics can refine targeted digital campaigns. This ensures that promotional materials resonate more effectively with specific patient demographics and healthcare providers, resulting in better engagement and return on investment (ROI).

Utilization of advanced analytics and AI will help users gain deep, actionable insights into customer behavior, preferences, and market trends. This data-centric approach will guide decision-making, product development, and marketing strategies.

These innovations will handle common inquiries, troubleshoot issues, and guide users through product information, thereby improving customer satisfaction and reducing support load on human agents. Our AI systems will continuously gather feedback and identify areas for improvement.

About Endonovo Therapeutics, Inc.

Endonovo Therapeutics is structured into two divisions: a Digital Health and Wellness Platform and a Legacy Division.

Digital Health and Wellness Platform: A Health and Wellness digital platform and e-commerce marketplace with AI integrated services and technology to streamline access for healthcare providers, enhance patient and retail customers engagement to capitalize and grow within the expanding digital health and wellness markets.
Legacy Division: as a commercial-stage developer primarily of noninvasive non-medical wearable Electroceuticals® therapeutic devices for general wellness

Cornerstone Marketing
Based on your post it is safe to say you have zero knowledge of investing or you are a dullard.

$0 sales last quarter. What does that tell you?

That clown posts links to a twitter post like it means anything anymore. ENDV is a penny stock scam.